Plenty of questions remain about the latest palazestrant data drop as investors hope for a Novartis buyout.

ASCO is fast approaching, but in the meantime Olema will have an important readout.

The new developer will focus on the crowded KRAS space and PI3Kα/AKT inhibition, which has been hit by toxicity issues.

Daiichi and AstraZeneca claim another breast cancer success, and further evidence of the ADC’s activity in very low HER2 expression.

Despite a growing presence outside cancer, the company wants to stay true to its “DNA”.

April will see the first big scientific meeting of the year, and could herald important data from Immutep and GSK.

However, lack of meaningful efficacy in Tropion-Lung01 suggests that datopotamab deruxtecan might be restricted to a histology-defined NSCLC subgroup.